Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 2/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CASR | P41180 | 2/20 | 0.30 |
| ▸ | PNP | P00491 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3091829 | 0.84 | POLB (0.33) | — | |
| SCHEMBL3090081 | 0.84 | TP53 (0.31) | SLC5A2 | |
| SCHEMBL3084727 | 0.81 | SLC6A4 (0.46) | SLC5A2SLC5A1 | |
| SCHEMBL3093428 | 0.72 | SLC5A2 (0.35) | SLC5A2SLC5A1HTR1DHTR1BIDO1 | |
| SCHEMBL3084929 | 0.71 | SLC5A2 (0.34) | SLC5A2SLC5A1HTR1DHTR1BIDO1 | |
| SCHEMBL3091180 | 0.70 | PNP (0.38) | SLC5A2SLC5A1HTR1DHTR1BIDO1 | |
| SCHEMBL8637440 | 0.70 | IDO1 (0.42) | SLC5A2SLC5A1HTR1DHTR1BIDO1 | |
| SCHEMBL7300578 | 0.68 | ALKBH5 (0.37) | ACHE | |
| SCHEMBL3074353 | 0.67 | SLC5A2 (0.34) | SLC5A2SLC5A1HTR1DHTR1BIDO1 | |
| SCHEMBL3090873 | 0.67 | SLC5A2 (0.34) | SLC5A2SLC5A1HTR1DHTR1BIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207134-B2 | Fused ring spiroketal derivative and use thereof as anti-diabetic drug | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20100234609-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2048152-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS DRUG FOR TREATING DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234609-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG | REN, WNK1, GCKR | SLC5A2 19/4885SLC5A1 16/4885HTR1D 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.